Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy

Learn more about:
Related Clinical Trial
Reproductive Outcomes After a Previous Episode of Tubal Ectopic Pregnancy in Patients Managed Expectantly and Surgically Relationship Between Ectopic Pregnancy and Thyroid Disorders Medical Treatment in Ectopic Tubal Pregnancy Evaluation of Different Doses of Letrozole in Ectopic Pregnancy Evaluation of Ipsilateral Tubal Patency After Conservative Medical or Surgical Treatment. Improving Mental Health Following Early PREgnancy Loss Using a Brief Cognitive Task Expectant Management of Ectopic Pregnancy Psychological Impact of Pregnancy of Unknown Location Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility Hysteroscopic Metroplasty in Unexplained Infertile Women With Dysmorphic Uterus Cornual Wedge Resection Outcome Pregnancies of Uncertain Location or Viability Research Randomized Population-Based Study on Chlamydia Trachomatis Screening Sonographic Assessment and Visualization of Ectopics in Emergency Medicine Kisspeptin Levels in Early Pregnancy RCT for Women With a Persisting Pregnancy of Unknown Location Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location Activin A and Inhibin A in Predicting Outcome of Pregnancies of Unknown Location After Assisted Reproductive Technology Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy Vitamin D in Ectopic Pregnancies Laparoscopic Tubal Preservation Surgery BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success The Correlation Between Uterine Endometrial Pattern and Ectopic Pregnancy Adnexal Mass After Methotrexate Treatment for Ectopic Pregnancies The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy Methotrexate Treatment for Ectopic Pregnancy Comparison of Two Different Approaches in the Surgical Treatment of Tubal Ectopic Pregnancy Two-Dose Methotrexate for Ectopic Pregnancy Ectopic Pregnancy Biomarkers The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy? Risk Factors of Ectopic Pregnancy Assessment of Biomarkers in Ectopic Pregnancy Risk of Ectopic Pregnancy and Variation of Luteal Estradiol and Progesterone Levels in IVF

Brief Title

Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy

Official Title

Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy

Brief Summary

      Objectives: To evaluate if, when considering expectant management in tubal ectopic pregnancy
      if the complementary use of Methotrexate could provide better results. We evaluate the
      success of treatment and the time required for titers of β-hCG to become negative. Methods: A
      double-blind randomized study, held at the Department of Obstetrics UNIFESP. The patients
      will be divided into two groups: in one patients will be administered a single intramuscular
      dose of 50 mg/m2 of Methotrexate and in the other patients will be prescribed Placebo
      intramuscularly. The monitoring will be done by measurement of β-hCG in the 4th and 7th day.
      When the decline of beta-hCG titers was > 15% in this interval, the patient was followed with
      weekly dosing of β-hCG until the titers become negative. The criterion of success is when the
      β-hCG was negative. The treatment failure occurs when surgery was necessary.

Study Phase

Phase 4

Study Type


Primary Outcome

success of treatment

Secondary Outcome

 Blood tests before treatment with Methotrexate and Placebo


Ectopic Pregnancy



Study Arms / Comparison Groups

Description:  Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2011

Completion Date

June 2013

Primary Completion Date

January 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Hemodynamic stability

          -  Initial β-hCG <2000 mIU / mL

          -  Titers of β-hCG in decline in 48 hours before treatment

          -  Adnexal mass <5.0 cm

          -  Desire for future pregnancy

        Exclusion Criteria:

          -  Alive embryo

          -  Ectopic pregnancy other than in tubal location

          -  Pregnancy of unknown location




18 Years - N/A

Accepts Healthy Volunteers



Julio Elito Junior, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Federal University of São Paulo

Study Sponsor

Julio Elito Junior, Study Director, Federal University of Sao Paulo

Verification Date

June 2013